Copyright Notice
Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.
Bookshelf ID: NBK501803PMID: 30000862
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-.
CASRN: 216503-57-0
Drug Levels and Effects
Summary of Use during Lactation
No information is available on the clinical use of alemtuzumab during breastfeeding. Because alemtuzumab is a large protein molecule with a molecular weight of 145,454 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, alemtuzumab should be used with caution or avoided during breastfeeding, especially while nursing a newborn or preterm infant.[1-4]
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Multiple Sclerosis) Glatiramer, Immune Globulin, Interferon Beta
References
- 1.
- Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: A systematic review. Obstet Gynecol. 2014;124:1157–68. [PubMed: 25415167]
- 2.
- Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013;19:835–43. [PubMed: 23319073]
- 3.
- Almas S, Vance J, Baker T, et al. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int. 2016;2016:6527458. [PMC free article: PMC4757692] [PubMed: 26966579]
- 4.
- Iyer P, Dobson R. Multiple sclerosis in pregnancy: A commentary on disease modification and symptomatic drug therapies. Neurol Ther. 2023;12:1–10. [PMC free article: PMC9837363] [PubMed: 36443593]
Substance Identification
Substance Name
Alemtuzumab
CAS Registry Number
216503-57-0
Drug Class
Breast Feeding
Milk, Human
Antineoplastic Agents
Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- User and Medical Advice Disclaimer
- LactMed App
- Drugs and Lactation Database (LactMed) - Record Format
- LactMed - Database Creation and Peer Review Process
- Fact Sheet. Drugs and Lactation Database (LactMed)
- Drugs and Lactation Database (LactMed) - Glossary
- LactMed Selected References
- Drugs and Lactation Database (LactMed) - About Dietary Supplements
- Breastfeeding Links
- Review Basiliximab.[Drugs and Lactation Database (...]Review Basiliximab.. Drugs and Lactation Database (LactMed®). 2006
- Review Golimumab.[Drugs and Lactation Database (...]Review Golimumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Cetuximab.[Drugs and Lactation Database (...]Review Cetuximab.. Drugs and Lactation Database (LactMed®). 2006
- Review Mepolizumab.[Drugs and Lactation Database (...]Review Mepolizumab.. Drugs and Lactation Database (LactMed®). 2006
- Review Trastuzumab.[Drugs and Lactation Database (...]Review Trastuzumab.. Drugs and Lactation Database (LactMed®). 2006
- Alemtuzumab - Drugs and Lactation Database (LactMed®)Alemtuzumab - Drugs and Lactation Database (LactMed®)
Your browsing activity is empty.
Activity recording is turned off.
See more...